Online inquiry

IVTScrip™ mRNA-Anti-FCGRT, ARGX-113(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ3232MR)

This product GTTS-WQ3232MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets FCGRT gene. The antibody can be applied in Myasthenia Gravis (MG) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_000484.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 351
UniProt ID P05067
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-FCGRT, ARGX-113(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ3232MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ5088MR IVTScrip™ mRNA-Anti-CSF2RA, CAM-3001(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA CAM-3001
GTTS-WQ11996MR IVTScrip™ mRNA-Anti-ERBB3, MM-121(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MM-121
GTTS-WQ14377MR IVTScrip™ mRNA-Anti-TNF, r-hTBP-1(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA r-hTBP-1
GTTS-WQ1110MR IVTScrip™ mRNA-Anti-MAPT, ABBV-8E12(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ABBV-8E12
GTTS-WQ7881MR IVTScrip™ mRNA-Anti-APCS, GSK-2398852(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA GSK-2398852
GTTS-WQ7240MR IVTScrip™ mRNA-Anti-STAB1, FP-1302(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA FP-1302
GTTS-WQ7470MR IVTScrip™ mRNA-Anti-TNFRSF4, GBR-830(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA GBR-830
GTTS-WQ12256MR IVTScrip™ mRNA-Anti-IL6R, MRA(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA MRA
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW